Lilly CEO says Foundayo drives growing share of new oral weight-loss prescriptions
Lilly chief Dave Ricks reported that the company's oral weight-loss pill Foundayo is capturing an expanding portion of new prescriptions in the United States.
Dave Ricks said that Foundayo is securing a larger slice of new oral weight-loss drug starts in the United States, with weekly growth in its market share. He noted that rollout to other nations is scheduled for later in the year. At the same time, Lilly broke ground on a $6.5 billion plant at Generation Park in Houston, which will also produce core chemicals for the company's cardiometabolic, oncology, immunology and neuroscience therapies and is expected to run by 2030.
Foundayo entered the U.S. market in April and generated $98 million in second-quarter revenue. The company cited the recent start of Medicare coverage for obesity drugs as a catalyst for further adoption. The new facility is part of Lilly's broader $27 billion investment in four additional sites, bringing total manufacturing spending since 2020 to over $50 billion.
Why it matters
Lilly's expanding oral weight-loss drug could reshape the U.S. obesity-treatment market and boost the company's growth.
In this story
